Nedosiran Sodium Patent Expiration
Nedosiran Sodium is used for treating Primary Hyperoxaluria Type 1 (PH1). It was first introduced by Novo Nordisk Inc
Nedosiran Sodium Patents
Given below is the list of patents protecting Nedosiran Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Rivfloza | US11286488 | Methods and compositions for inhibiting expression of LDHA | Oct 12, 2038 | Novo |
| Rivfloza | US11661604 | Methods and compositions for inhibiting expression of LDHA | Oct 12, 2038 | Novo |
| Rivfloza | US11053502 | Therapeutic inhibition of lactate dehydrogenase and agents therefor | Oct 29, 2035 | Novo |
| Rivfloza | US10351854 | Therapeutic inhibition of lactate dehydrogenase and agents therefor | Oct 09, 2035 | Novo |
| Rivfloza | US10738311 | Therapeutic inhibition of lactate dehydrogenase and agents therefor | Oct 09, 2035 | Novo |
| Rivfloza | US11359203 | Therapeutic inhibition of lactate dehydrogenase and agents therefor | Oct 09, 2035 | Novo |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Nedosiran Sodium's patents.
Latest Legal Activities on Nedosiran Sodium's Patents
Given below is the list recent legal activities going on the following patents of Nedosiran Sodium.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Patent eCofC Notification | 16 Jul, 2024 | US11286488 |
| Email Notification Critical | 16 Jul, 2024 | US11286488 |
| Patent eCofC Notification | 16 Jul, 2024 | US11286488 |
| Recordation of Patent eCertificate of Correction | 16 Jul, 2024 | US11286488 |
| Post Issue Communication - Certificate of Correction | 12 Jul, 2024 | US11661604 |
| Mail Pub Notice re 312 amendment | 01 Jul, 2024 | US11661604 |
| Email Notification Critical | 01 Jul, 2024 | US11661604 |
| POST ISSUE OTHER COMMUNICATION TO APPLICANT- CERTIFICATE OF CORRECTION | 26 Jun, 2024 | US11661604 |
| Post Issue Communication - Certificate of Correction Denied | 26 Jun, 2024 | US11661604 |
| Post Issue Communication - Certificate of Correction | 25 Jun, 2024 | US11286488 |
Nedosiran Sodium's Family Patents
